Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.25
-4.1%
$11.74
$9.46
▼
$23.29
$998.30M1.141.67 million shs1.18 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-4.09%-10.43%+17.80%-32.80%-13.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.25
-4.1%
$11.74
$9.46
▼
$23.29
$998.30M1.141.67 million shs1.18 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-4.09%-10.43%+17.80%-32.80%-13.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.60
Moderate Buy$31.33178.52% Upside

Current Analyst Ratings Breakdown

Latest MLTX and IMGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/12/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Set Price TargetOutperform$34.00
11/6/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Initiated CoverageBuy$57.00
10/5/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Reiterated RatingBuy$50.00
9/16/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Reiterated RatingOverweight
8/21/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.67N/AN/AN/AN/A-79.95%-56.40%N/A

Latest MLTX and IMGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.8326-$0.93-$0.0974-$0.93N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.26
9.13
9.13

Institutional Ownership

CompanyInstitutional Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%

Insider Ownership

CompanyInsider Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable

Recent News About These Companies

What is HC Wainwright's Estimate for MLTX FY2026 Earnings?
How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing
MoonLake Immunotherapeutics (MLTX) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$11.25 -0.48 (-4.09%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$11.46 +0.21 (+1.88%)
As of 11/17/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.